Structure-Activity Relationship

"Structure-Activity Relationship" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups.

Descriptor ID	D013329
MeSH Number(s)	G02.111.830 G07.690.773.997
Concept/Terms	Structure-Activity Relationship Structure-Activity Relationship Relationship, Structure-Activity Relationships, Structure-Activity Structure Activity Relationship Structure-Activity Relationships

Below are MeSH descriptors whose meaning is more general than "Structure-Activity Relationship".

Biological Sciences [G]
Chemical Phenomena [G02]
Biochemical Phenomena [G02.111]
Structure-Activity Relationship [G02.111.830]
Physiological Phenomena [G07]
Pharmacological and Toxicological Phenomena [G07.690]
Pharmacological Phenomena [G07.690.773]
Structure-Activity Relationship [G07.690.773.997]

Below are MeSH descriptors whose meaning is related to "Structure-Activity Relationship".

Below are MeSH descriptors whose meaning is more specific than "Structure-Activity Relationship".

Structure-Activity Relationship
Quantitative Structure-Activity Relationship

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Structure-Activity Relationship" by people in this website by year, and whether "Structure-Activity Relationship" was a major or minor topic of these publications.

Bar chart showing 318 publications over 30 distinct years, with a maximum of 23 publications in 2015

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1995	0	4	4
1996	0	6	6
1997	0	2	2
1998	0	4	4
1999	0	2	2
2000	0	5	5
2001	0	4	4
2002	0	11	11
2003	0	10	10
2004	0	12	12
2005	0	7	7
2006	0	11	11
2007	1	13	14
2008	0	14	14
2009	0	11	11
2010	0	21	21
2011	0	16	16
2012	0	16	16
2013	0	21	21
2014	2	16	18
2015	0	23	23
2016	1	18	19
2017	0	13	13
2018	0	11	11
2019	0	10	10
2020	0	17	17
2021	0	7	7
2022	0	1	1
2023	0	5	5
2024	0	3	3

Below are the most recent publications written about "Structure-Activity Relationship" by people in Profiles.

VanKoten HW, Pence BC, Klinkenberg JR, Das S, Patterson SE. Synthesis and evaluation of anti-Giardia activity of oseltamivir analogs. Bioorg Med Chem Lett. 2025 Feb 01; 116:130035.

View in: PubMed
Delaitre C, Boisbrun M, Acherar S, Dias A, Kleinclauss A, Achard M, Colin M, Nguyen TM, Humbert N, Chmeis K, Martinez KL, Gilles N, Robin P, Lecat S, Dupuis F. Synthesis and Pharmacological Characterization of Fluorescent Ligands Targeting the Angiotensin II Receptors Derived from Agonists, ?-Arrestin-Biased Agonists, and Antagonists. J Med Chem. 2024 Nov 28; 67(22):20275-20297.

View in: PubMed
Elbatrawy AA, Ademoye TA, Alnakhala H, Tripathi A, Plascencia-Villa G, Zhu X, Perry G, Dettmer U, Fortin JS. Exploring the rhodanine universe: Design and synthesis of fluorescent rhodanine-based derivatives as anti-fibrillar and anti-oligomer agents against a-synuclein and 2N4R tau. Bioorg Med Chem. 2024 Dec 15; 116:117990.

View in: PubMed
Peng X, Guo S, Zheng S, Hossain A, Zhang C, Mottamal M, Skripnikova E, Ma P, Martinez-Carter K, Zhang Q, Abedin F, Huckaba T, Wang G. Discovery of Oral Degraders of the ROS1 Fusion Protein with Potent Activity against Secondary Resistance Mutations. J Med Chem. 2024 Oct 24; 67(20):18098-18123.

View in: PubMed
Metibemu DS, Adeyinka OS, Falode J, Hampton T, Crown O, Ojobor JC, Narayanan A, Julander J, Ogungbe IV. Inhibitor of the non-structural protein 2 protease shows promising efficacy in mouse models of chikungunya. Eur J Med Chem. 2024 Nov 15; 278:116808.

View in: PubMed
Liu W, Mousa AAK, Hopkins AM, Wu YF, Thu KL, Campbell M, Lees SJ, Ramachandran R, Hou J. Lysophosphatidic Acid Receptor 1 (LPA1) Antagonists as Potential Migrastatics for Triple Negative Breast Cancer. ChemMedChem. 2024 Aug 19; 19(16):e202400013.

View in: PubMed
Liang Z, Candib A, Soriano-Castell D, Fischer W, Finley K, Maher P. Fragment-based drug discovery and biological evaluation of novel cannabinol-based inhibitors of oxytosis/ferroptosis for neurological disorders. Redox Biol. 2024 06; 72:103138.

View in: PubMed
Upadhyay DB, Mokariya JA, Patel PJ, Patel SG, Das A, Nandi A, Nogales J, More N, Kumar A, Rajani DP, Narayan M, Kumar J, Banerjee S, Sahoo SK, Patel HM. Indole clubbed 2,4-thiazolidinedione linked 1,2,3-triazole as a potent antimalarial and antibacterial agent against drug-resistant strain and molecular modeling studies. Arch Pharm (Weinheim). 2024 Apr; 357(4):e2300673.

View in: PubMed
Swain RM, Sanchez A, Gutierrez DA, Varela-Ramirez A, Aguilera RJ. Thiophene derivative inflicts cytotoxicity via an intrinsic apoptotic pathway on human acute lymphoblastic leukemia cells. PLoS One. 2023; 18(12):e0295441.

View in: PubMed
Mito S, Cheng B, Garcia BA, Yee Ooi X, Gonzalez D, Ruiz TC, Elisarraras FX, Tsin A. SAR study of niclosamide derivatives for neuroprotective function in SH-SY5Y neuroblastoma. Bioorg Med Chem Lett. 2023 11 15; 96:129498.

View in: PubMed

People

Explore

Similar Concepts

Top Journals